The global 23 Valent Pneumococcal Polysaccharide Vaccine market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on 23 Valent Pneumococcal Polysaccharide Vaccine volume and value at global level, regional level and company level. From a global perspective, this report represents overall 23 Valent Pneumococcal Polysaccharide Vaccine market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of 23 Valent Pneumococcal Polysaccharide Vaccine in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their 23 Valent Pneumococcal Polysaccharide Vaccine manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
23-Valent Pneumococcal Polysaccharide Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine contains 23 of the most common types of pneumococcal bacteria.
23-Valent Pneumococcal Polysaccharide Vaccine is for use only in adults and children who are at least 2 years old. For children younger than 2 years old, another vaccine called Prevnar (pneumococcal conjugate vaccine [PCV] 7-valent) is used, usually given between the ages of 2 months and 15 months.
Scope of the Report:
North America is the largest supplier and consumption market of 23-Valent Pneumococcal Polysaccharide Vaccine, with a production market share nearly 70% and sales market share nearly 28% in 2015. Because Sanofipasteur, a competitor from Europe, transferred its vaccine type gradually, the production market share of North America in the world has enjoyed a dramatic increase.
The second place is EU, following North America with production market share of 15% and sales market share nearly 20% in 2015.China is another important market of 23-Valent Pneumococcal Polysaccharide Vaccine, enjoying 10% production market share and 15% sales market share in 2015.
The worldwide market for 23-Valent Pneumococcal Polysaccharide Vaccine is expected to grow at a CAGR of roughly 16.3% over the next five years, will reach 3830 million US$ in 2025, from 1550 million US$ in 2019, according to a new Research study.
This report focuses on the 23-Valent Pneumococcal Polysaccharide Vaccine in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Get a FREE sample Copy of this report : https://www.1marketresearch.com/market-reports/23-valent-pneumococcal-polysaccharide-vaccine-market-industry-report-103001#requestSample
Market Segment by Manufacturers, this report covers
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Single Dose Vial
Market Segment by Applications, can be divided into
For Children (2-10)
For Person (10-64)
For The Old (¥65)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe 23-Valent Pneumococcal Polysaccharide Vaccine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of 23-Valent Pneumococcal Polysaccharide Vaccine, with price, sales, revenue and global market share of 23-Valent Pneumococcal Polysaccharide Vaccine in 2017 and 2018.
Chapter 3, the 23-Valent Pneumococcal Polysaccharide Vaccine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the 23-Valent Pneumococcal Polysaccharide Vaccine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, 23-Valent Pneumococcal Polysaccharide Vaccine market forecast, by regions, type and application, with sales and revenue, from 2019 to 2025.
Chapter 13, 14 and 15, to describe 23-Valent Pneumococcal Polysaccharide Vaccine sales channel, distributors, customers, research findings and conclusion, appendix and data source.